Mode
Text Size
Log in / Sign up
N/A Completed N=57 Randomized Treatment

Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease

Meibomian Glands · Dry Eye Syndromes
Source: ClinicalTrials.gov NCT03226769 ↗
Enrolled (actual)
57
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcomePrimary: Change From Baseline in Meibomian Gland Dysfunction (MGD) Impact Questionnaire Score — -0.4; -0.3; -0.4; -0.2 score on scale — p=0.9788

Summary

This study will compare the safety and efficacy of TrueTear™ to standardized moist heat compress (Thermalon® Dry Eye Compress) for the treatment of Meibomian Gland Disease (MGD).

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Meibomian Gland Dysfunction (MGD) Impact Questionnaire Score
-0.4; -0.3; -0.4; -0.2; -0.3; -0.4 0.9788
PRIMARY
Change From Baseline in MGD Symptoms Questionnaire Score
-0.2; -0.1; -0.2; -0.2; -0.3; -0.5 0.5457

Eligibility Criteria

Inclusion Criteria

  • Dry eye disease or Meibomian Gland Disease as evaluated by Standard Participant Evaluation for Dryness (SPEED) score, Schirmer test, Tear film breakup time and other applicable objective measures at the Screening and Baseline Visits.
  • Use of an artificial tear product, lid hygiene, omega-3 supplementation, antibiotics for the treatment of dry eye disease or Meibomian Gland Disease within one year of the Screening Visit.

Exclusion Criteria

  • Chronic or recurrent epistaxis, coagulation disorders or other conditions that may increase the risk of bleeding.
  • History of nasal or sinus surgery.
  • Vascularized polyp, deviated septum or severe nasal airway obstruction at the Screening visit.
  • Intraocular and extraocular surgery in either eye within three months of the Screening Visit or refractive surgery within twelve months of the Screening Visit.
  • Cardiac demand pacemaker, implanted defibrillator, or other active implanted metallic or active implanted electronic device in the head.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03226769). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search